An observational study using an investigator-initiated registry followed off-label treatment with ambroxol of 38 patients with Gaucher’s disease and 3 PD patients with GBA1 mutations for a median duration of 19 months (median dose of 435 mg/day) [32]. The gene discussed is GBA1; the disease is Parkinson disease.